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Abstract Severe a1-anti-trypsin (AAT) de¢ciencyimplies ahighriskofpulmonaryemphysemadevelopment.Thepos-
sible relationship betweenpartial de¢ciencies of this enzyme andbronchial asthma remains controversial.The objective
ofthis studywas to ascertainthedistributionof AATphenotypesin anon-selectedasthmaticpatientpopulation.Across-
sectionalstudyona sampleof111patientswith asthmawascarriedout.Demographic andclinicalvariableswere collected
with serum IgE concentrations, plasma eosinophil number and serum AAT concentrations determined, together with
the Pi phenotype. Asthma wasmild in 36 (32?4%) patients, moderate in 45 (40?5%) and severe in 30 (27%).No di¡er-
enceswere observed in eosinophil countor serum IgE or AAT concentrations amongpatientswith di¡erentdegrees of
severity.Twenty-two (19?8%) asthmatics with de¢cient phenotypes for AATwere identi¢ed, distributed equally in all
severity stages ofthe disease.No signi¢cantdi¡erenceswere foundinclinical and functionalcharacteristics, or in asthma
morbidity between PiMM and PiMS patients or the heterozygote group (PiMS and PiMZ). Eosinophil count and IgE
concentrations did notdi¡er signi¢cantly between asthmaticswith normalphenotype andheterozygotes.In conclusion,
the distribution of AAT phenotypes in asthmatic patients did not di¡er from that found in the general population.
Heterozygote phenotypes for the de¢ciencydo not appear to confer greater severityordi¡erentclinical expression of
asthma in adults.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1237, available online athttp://www.idealibrary.comon
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a1-anti-trypsin (AAT) de¢ciency is a hereditary disease
characterized by decreased serum concentrations of
the protein and is manifested clinically by an increased
predisposition towards the development of pulmonary
emphysema in early stages of life (1). The relationship-
betweenAAT de¢ciency and other diseases, particularly
those of the respiratory system, has been a topic of
intense research since the de¢ciency was discovered in
the early 1960s (2). Previous studies demonstrated the
association of the de¢ciency with di¡erent autoimmune
diseases (3); however, its possible in£uence on the
onset and severity of other processes such asReceived 4 April 2001, accepted in revised form 24October 2001and
published online14 January 2002.
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E-mail: marcm@separ.esbronchiectasis (4) or bronchial asthma (5) is more
controversial.
Thepresence of a de¢cient S allelehasbeen associated
with a high risk of non-speci¢c bronchial hyper-response
(6), although other studies failed to show a greater fre-
quency of protease inhibitor (Pi) MS individuals among
asthmatics comparedwith the general population (7). Si-
milarly, the inheritance of a de¢cient Z allele in the het-
erozygous form (PiMZ) appears to imply greater
severity of the asthmatic disease in children and
adolescents (8,9), although its importance in adults re-
mains unknown.Given the high prevalence of the S allele
in the Spanish population,which ismuchhigher than that
found in other European areas (10,11), this country o¡ers
an ideal scenario for observing the in£uence of this var-
iant on di¡erent diseases.The present work aims to as-
certain the distribution of de¢cientAAT phenotypes in a
non-selected population of patients with bronchial asth-
ma. Furthermore, we will attempt to investigate the
possible in£uence of de¢cient AAT phenotypes on
asthma severity and clinical expression.
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This was a cross-sectional study of patients with
bronchial asthma identi¢ed and treated in a hospital
outpatient department between September 1996 and
September 1997. Candidates for the study were those
who met the following inclusion criteria: age over 14
years with the diagnosis of bronchial asthma and
symptomatic disease during the previous year. Each
patient satis¢ed the international classi¢cation criteria
for asthma, with symptoms of episodic wheezing, cough
and shortness of breath which responded to bronchodi-
lators, and reversible air£ow obstruction documented
in at least one previous pulmonary function study (12).
Exclusion criteria were: (a) current smoking of more
than ¢ve cigarettes per day or previous accumulated
exposure of more than 10 packs-year; (b) patients with
suspected occupational asthma or another respiratory
disease caused by their occupation; (c) radiological
alterations suggestive of respiratory disease other than
asthma or which, by its extension, might a¡ect respira-
tory function data; (d) presence of a restrictive pattern
in respiratory function tests [total lung capacity (TLC)
o80% of theoretical value] and (e) co-existence of other
diseases that might alter clinical data or respiratory
function values (heart failure, anaemia, systemic dis-
eases, muscular or thoracic cage disorders, morbid obe-
sity and sleep apnoeas).
All patients were interviewed by either of the same
two researchers (M.T., E.B.) at the general hospital where
inclusion criteriawereveri¢ed, and demographic, clinical
and morbidity data were collected. Asthma-related
morbidity referred to the previous year included fre-
quency of exacerbations or asthma attacks, number of
visits to the family physician, number of visits to the spe-
cialist, number of hospitalizations, number of visits to an
emergency service and medication used for asthma
treatment during the past year. A standard question-
naire on symptoms and asthma-related morbidity was
used (13).
Analytical variables included quanti¢cation of
eosinophils in blood and immunoglobulin E (IgE) value
which was determined by £uoroimmunoassay with the
Pharmacia Cap System IgE, FEIA (Uppsala, Sweden)
equipment. a1-anti-trypsin (AAT) concentrations were
determined by immunonephelometry with an ArrayTM
Protein System autoanalyser (Beckman-Instruments,
Brea, California, U.S.A.). AAT Pi (proteinase inhibitor)
phenotypes were determined by the isoelectrofocusing
technique in polyacrylamide gels according to the techni-
que described previously (14). Respiratory function ex-
amination was always performed in stable phase
following Spanish Society of Pneumology and Thoracic
Surgery (SEPAR) recommendations (15) and included: (a)
forced spirometry; (b) bronchodilator test, considered
positive when the increase in forced expiratory volumein1sec (FEV1) was equal to or greater than 200ml and at
12% following the inhalation of 400ml of salbutamol MDI
with inhalation chamber; (c) static pulmonary volumes
by plethysmography using a MasterLab version 2.1
(Wˇrzburg, Germany); and (d) carbon monoxide
transfer test performed according to the single respira-
tion technique using the same equipment. Values re-
corded were post-bronchodilatador and expressed as
litres and % of predicted. Reference values were those
of Roca et al. (16).
Patients were ¢nally divided into three asthma sever-
itygroups according to the International Classi¢cation of
Asthma (12). Patients were characterized as having mild
asthma if they presented daytime symptoms more than
twice a week but less than once a day, night-time symp-
tomsmore than twice a month, and pulmonary function
with FEV1 or peak expiratory £ow (PEF) 480% pre-
dicted and PEF variability between 20 and 30%. Moder-
ate asthma was considered when patients presented
daily symptoms, daily use of short-acting b2-agonists and
exacerbations that may interfere with daily activities,
night-time symptoms more than once a week, and FEV1
or PEF between 60% and 80% predicted. Severe asthma
was diagnosed when the patients ful¢lled the following
characteristics: continuous symptoms with limitation in
daily activities and frequent exacerbations, frequent
night-time symptoms, FEV1or PEFo60% predicted and
PEF variability higher than 30%. Patients with mild
intermittent asthma and persistent mild asthma were
included in themild asthma category.
Statistical analysis
The distribution ofAATphenotypes in the asthmatic po-
pulation was compared with that obtained previously in
a reference population.This population consisted of 440
unselected, non-related healthy individuals from the
samegeographic areawho attended thepreventivemedi-
cine department of our hospital for a regular check-up.
Sample size was calculated based on an expected
prevalence of PiMZ individuals of 2%. This population
was described in detail in a previous publication (10).
Comparison of means among groups was performed
by analysis of variance (ANOVA) for quantitative
variables and the chi-square test for qualitativevariables.
A value of Po0?05 was considered to be statistically
signi¢cant.
RESULTS
Study population
During the study period, 111 patients with the diagnosis
of bronchial asthma, who ful¢lled the inclusion criteria
and were free of exclusion criteria, were recruited.The
majority were women (64?4%) with a mean age of 34?5
188 RESPIRATORYMEDICINEyears (SD=16?3 years). With regard to smoking, the
majority (80 subjects, 72?1%) had never smoked.
Demographic and clinical characteristics of the patients
are listed inTable1.
According to the international classi¢cation, 36
(32?4%) patients were classi¢ed as mild, 45 (40?5%) as
moderate and 30 (27%) as severe asthmatics.
Patients with severe asthma were signi¢cantly older
than thosewithmild^moderate asthma (Po0?01). Mean
age at onset of asthma symptomswas19?1years (SD=16?6
years), with no signi¢cant di¡erences among the groups.
A history of idiosyncrasy to aspirin was reported in 16
(14?4%); this was less frequent among moderate asth-
matics (8?8%), but again without reaching statistical sig-
ni¢cance (P=0?21).
Almost half the patientswho participated in the study
reported wheezing; among severe patients, the pre-
sence of audible wheezing reached 74%, but only 25% in
mild and 51% inmoderatepatients (Po0?05).Only 32%of
patients required admission in the 6 months prior to the
study, andof thesenine (8?1%)were admitted to an inten-
sive care unit.
Fifty-three patients (55?8% of cases) required courses
of oral corticosteroids in the previous year to control
their asthma symptoms.
Theresults of respiratory function tests and analytical
determinations are shown in Table 2. It is noteworthy
that the most severe patients presented signi¢cantly
more altered spirometric values, with decreases in
forced vital capacity (FVC) (%), FEV1, FEV1 (%) and
FEV1/FVC (Po0?0001 in all comparisons). In turn, static
pulmonary volumes, total lung capacity (TLC) (%), resi-
dual volume (RV) and RV (%) were signi¢cantly higher in
severe patients, showing greater air-trapping (Po0?01,
Po0?003 and Po0?03, respectively). No signi¢cant
di¡erences were observed in carbon monoxide (CO)
di¡usion capacity.
Mean blood eosinophil value was 426?8 elements
mm3 (SD=348) and mean serum IgE 361Ul1 (SD=
475Ul1), with no signi¢cant di¡erences among patients
with di¡erent stages of disease severity.
a1-anti-trypsin concentrations and Pi
phenotype determination
Mean AAT value was 154?3mgdl1 (SD= 32?5mgdl1).
Normal serum concentrations in our laboratory are
116^232mgdl1 (21^41mMl1) (10). No signi¢cant di¡er-
ences were found when AATvalues were compared in
each of the asthmatic patient groups classi¢ed according
to severity criteria (Table 2).
Twenty-two (19?8%) asthmatic carriers of de¢cient
phenotypes for AATwere identi¢ed. No individual with
severe AAT de¢ciency (PiZZ) was identi¢ed among the
asthmatic population.Frequencyof de¢cientphenotypeswas distributed equally in all the asthma severity
categories (Table 2).
The distribution of the di¡erent AAT phenotypes de-
tected in the asthmatic population was similar to that
described in the general population of the same
geographical area, as shown inTable 3.
On analysing the results obtained by grouping
patients according to their Pi phenotype, no di¡erences
were observed between groups according to severity
among asthmatics with normal PiMM phenotype and
PiMS heterozygotes (chi-square test, P= 0?45). Neither
were di¡erences foundwhen all asthmatics with hetero-
zygote phenotype (PiMS, PiMZ or PiSZ) were consid-
ered together (chi-square test, P=0?34). No signi¢cant
di¡erences could be demonstrated in the clinical charac-
teristics ormorbiditymarkers of asthma amongpatients
with PiMM phenotype and those with PiMS
(Table 4), or the group of heterozygotes considered
together (data not shown).
With respect to analytical and respiratory function
variables, patients with PiMS phenotype presented
mean AAT values lower than those of PiMM
patients, 138?5mgdl1 (SD=32) vs. 160?1mgdl1
(SD=28?8; Po 0?01). Eosinophil count pulmonary
function test results and IgE concentrations
were not signi¢cantly di¡erent between asth-
matics with normal phenotype and heterozygotes
(Table 5).
DISCUSSION
The results of the present study indicate that the preva-
lence of di¡erent AAT phenotypes in a non-selected
population of asthmatic patients does not di¡er from
thatwe found in a sample of the general population from
the same geographical area. Furthermore, the presence
of a partial AAT de¢ciency does not imply greater sever-
ity or di¡erent clinical expression of asthma. SevereAAT
de¢ciency in the general population is rare. A recent
study in Spain estimated the allelic frequency of the Z
gene to be 1?5%, which implies an estimate of 225 PiZZ
homozygotespermillion, according to theHardy^Wein-
berg formula (10). However, only 223 patients had been
diagnosed up to1998 (17).On the other hand, carriers of
moderate AAT de¢ciencies are more frequent; several
studies have estimated a PiMS prevalence of 5% in
Europeans (18), with a maximum in the Iberian peninsula
where theprevalence liesbetween15% and 20% (10,11,18).
Similarly, the frequency of PiMZ heterozygotes found in
our population of asthma patients was 1% and that of
PiMS heterozygotes,17%.
The possible role of the S allele in the onset of
asthmatic disease remains controversial. Earlier
studies suggested that the prevalence of the PiMS
phenotype was higher in asthmatic subjects than in the
TABLE 1. Demographic and clinical characteristics of patients classi¢ed according to asthma severity
Features Global
(n=111)
Mild asthma (n=36) Moderate asthma (n=45) Severe asthma (n=30) P*
Sex, female (%) 71 (64) 23 (64) 28 (62?3) 20 (66?6) 0?926
Age, years (SD) 34?5 (16?2) 32 (16) 30 (14) 42?4 (17) o0?01
Smokers (%) 31 (27?9) 12 (33?3) 13 (28?9) 6 (20) 0?5
Clinicalvariables
AASw idiosyncrasy (%) 16 (14?4) 5 (13?9) 4 (8?8) 7 (23?3) 0?21
Rhinitis (%) 75 (72?1) 20 (62?5) 34 (79) 21 (72?4) 0?42
Daily wheezing (%) 48 (50?9) 7 (25) 21 (51?2) 20 (74) o0?05
Exertion dyspnoea (%) 47 (45) 0 (0) 26 (59) 21 (72?4) o0?001
Asthmamorbidity
Onsetof symptoms, years (SD) 19?1 (16.6) 21?8 (18) 14?7 (14) 22?4 (16) 0?12
No. of admissionsprevious year per patient (range) 0?4 (0^5) 0?3 (0^1) 0?3 (0^1) 0?6 (0^5) 0?15
No. of oral courses of steroids previous year per patient (range) 0?62 (0^6) 0?3 (0^2) 0?6 (0^2) 0?9 (0^6) o0?05
*Comparison amongpatientswith di¡erentdegrees of asthma severity, Student’s t-testor chi-square test.
wAAS= aspirin.
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TABLE 3. AAT phenotype distribution amongpatientswith asthma and its comparisonwiththe generalpopulation *
Phenotype Asthma
(n=111)
CI 95% Generalpopulation
(n=440)
CI 95%
MM 89 (80?2%) 72?8^87?6% 333 (75?7%) 71?7^79?7%
MS 19 (17?1%) 10?1^24?1% 84 (19?1%) 15?4^22?8%
MZ 2 (1?8%) 0?2^6?3% 14 (3?2%) 1?7^5?2%
SZ 1 (0?9%) 0?02^4?8% 0 F
ZZ 0 F 0 F
Other 0 F 9 (2%) 0?9^3?8%
*Data taken from (10).
TABLE 4. Demographic and clinical characteristics of patientswith asthma according to themost frequent AAT phenotypes
MM phenotype
(n=89)
MSphenotype
(n=19)
Sex, female (%) 59 (66?3) 10 (52?7)
Age, years (SD) 35?7 (17) 28?7 (13)
Smokers, (%) 26 (29?2) 5 (26?3)
Clinicalvariables
AASidiosyncrasy (%) 13 (14?6) 3 (15?7)
Rhinitis (%) 57 (68?6) 15 (83?2)
Wheezing (%) 41 (52?5) 5 (31?2)
Exertion dyspnoea (%) 38 (46?2) 8 (42)
Asthmamorbidity
Onsetof symptoms, years (SD) 20 (16?8) 14 (15?4)
No. of admissionsprevious year (range) 0?41 (0^5) 0?42 (0^5)
No. of courses of oral steroids previous year per patient (range) 1?24 (0^6) 0?73 (0^6)
Asthma severity
Mild asthma (%) 30 (33?7) 5 (26?3)
Moderate asthma (%) 33 (37) 10 (52?6)
Severe asthma (%) 26 (29?2) 4 (21)
All comparisonsbetween PiMS andheterozygoteswith PiMMwerenot signi¢cant.
TABLE 2. Laboratory andpulmonary function data of patients according to asthma severity
Characteristics Global
(n=111)
Mild asthma
(n= 36)
Moderate asthma
(n= 45)
Severe asthma
(n=30)
P
De¢ciencyphenotype (%) 20 16?7 26?7 13?4 0?35
AAT (mgdl1) 154 (32) 155?5 (33) 148 (30) 161 (33) NS
Eosinophilsmm3* 426 (348) 439?2 (360) 380 (303) 494 (407) NS
IgE (Ul1)w 361 (475) 344?4 (315) 399 (605) 317 (364) NS
PFR
FVC (ml) 3548 (1157) 3875 (1128) 3571 (957) 3090 (1359) o0?05
FVC (% pred.) 90 (17) 101 (12) 86 (11) 83 (23) o0?0001
FEV1 (ml) 2771 (995) 3209 (912) 2814 (823) 2115 (1046) o0?0001
FEV1 (% pred.) 86 (20) 101 (11) 84 (15) 70 (24) o0?0001
FEV1/FVC (% pred.) 77 (11) 82 (8) 78 (10) 68 (12) o0?0001
TLC (ml) 5758 (1453) 5764 (1653) 5562 (1200) 6094 (1532) NS
TLC (% pred.) 110 (17) 106 (17) 104 (13) 115 (20) o0?01
RV (ml) 2279 (937) 2067 (707) 2060 (621) 2975 (1320) o0?003
RV (% pred.) 146 (49) 139 (46) 136 (39) 173 (59) o0?03
KCO (% pred.) 100 (16) 101 (16) 101 (14) 99 (21) NS
Standard deviation inparentheses.
*Normalvalues of blood eosinophils: 50^500 elementsmm3.
wNormalvalues of serum IgE (authomaticmethod): 0^1000Ul1.
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TABLE 5. Functional and analytical data of patients with
asthma according to themost frequent AAT phenotypes
MM phenotype
(n=89)
MSphenotype
(n=19)
X (DE)
AAT (mgdl1) 160 (28?8) 138?5 (32?4)*
Eosinophilsmm3 435?6 (359?2) 428?7 (315?1)
IgE (Ul1) 383?3 (482?8) 286 (484?2)
PFR
FVC (ml) 3443?4 (1032?4) 3883?1 (1520?7)
FVC (% pred.) 90?1 (15?2) 90?5 (23?8)
FEV1 (ml) 2686?2 (952?4) 3060?5 (1094)
FEV1 (% pred.) 86 (20) 87?4 (24)
FEV1/FVC 76?7 (12?1) 79?7 (8?8)
TLC (ml) 5667?4 (1404?4) 5980 (1625?5)
TLC (% pred.) 111?5 (18?3) 105?7 (14)
RV (ml) 2315?7 (1020) 2142?7 (581?4)
RV (% pred.) 146?3 (51?6) 149?1 (42?5)
KCO (% pred.) 100?6 (17) 102?2 (17?3)
*Comparison with MM Po0?01.The remaining compari-
sonswere not signi¢cant.
a1-ANTI-TRYPSINPHENOTYPESANDASTHMA 191general population (19^22), with a ratio among preva-
lences between1?16 and 3?5, although in some cases this
di¡erence did not reach signi¢cance (8,22).Greater non-
speci¢c bronchialhyper-responsivenesshas alsobeende-
scribed in PiMS phenotype carriers, which would favour
a possible increase in theprevalence of asthma in this po-
pulation (6). In our study, the asthmatics with PiMS phe-
notype for AAT did not present di¡erential
characteristics compared with the asthmatic carriers of
the non-de¢cient PiMMphenotype, although AATvalues
were signi¢cantly lower. Neither did we observe di¡er-
ences in the results of respiratory function tests, blood
eosinophil values or plasma IgE concentrations.These re-
sults are similar to those of other series in the literature,
which failed to ¢nd a greater prevalence of the PiMSphe-
notype in asthmatic patients (8).
A possible explanation for these discrepancies would
lie in the age of thepatients studied. According to Anaud
et al. (20), asthmatic children with PiMS phenotype
presented bronchial hyper-responsiveness at earlier
ages, which was also observed in relation to the PiMZ
heterozygote phenotype. Other studies conducted in
asthmatic patients, half of whom were under the age
of 18, showed that 62?5% of PiMS and only 30% of
PiMM presented some altered value on spirometry (23).
In contrast, works that included a majority of adult
asthmatics, as in the present study, have been unable to
demonstrate a greater prevalence of de¢cient pheno-
types among asthma patients comparedwith the general
population (24,25).
Something similar occurs with the Z alleles. The
results of some studies suggest that the PiMZ heterozy-gote phenotype favours the onset of atopy, since PiMZ
asthmatics present a greater frequency of accompanying
atopic dermatitis than PiMS and PiMMasthmatics (26). In
another study conducted in a population with a high
incidence of bronchial asthma, such as the native popula-
tion of Puerto Rico (27), a higher prevalence of symp-
toms consistent with atopy was observed in PiMS and
PiMZ heterozygote individuals compared with PiMM
subjects. In contrast, in our study we did not ¢nd a
greater frequency of atopy in carriers of variants
PiMS and PiMZ, assessed by the presence of clinical fea-
tures, together with eosinophil count or IgE concentra-
tions. Nevertheless, one previous study found that
homozygotes PiZZwith COPD presented a higher inci-
dence of signs and symptoms of asthma thanCOPDwith
normal phenotypes (28).Unfortunately, we cannot com-
pare these results with our study, since no individuals
with severe de¢ciency (PiZ) were identi¢ed in our asth-
ma population.
In addition to a greater risk of asthma, attempts have
been made to associate de¢cient AAT phenotypes with
greater severity of the asthmatic disease. Katz et al. (8)
found a higher number of phenotypic Z variants in a
group of corticosteroid-dependent asthmatic patients
compared with a non-corticoid-dependent group when
studying a population of children with asthma, although
this di¡erence did not reach statistical signi¢cance. The
results of ourworkdo not support amore severe clinical
expression of the disease in adultswith PiMZphenotype
comparedwith non-de¢cient individuals.
The mechanism by which AAT de¢ciency could
predispose to asthma is not well known. This protein
has important biological e¡ects which include a
modulating e¡ect on lymphocyte function; individuals
with AAT de¢ciency present a lack of lymphocyte func-
tion inhibition demonstrated by an exaggerated delayed
hypersensitivity reaction as a response, e.g. to intra-
dermal tuberculin test (29). This lymphocytic alteration
has been proposed as a cause of the increase in the sus-
pectibility of AAT-de¢cient patients to su¡er from auto-
immune diseases (3,30). Nevertheless, humoral
immunity evaluated as serum immunoglobulin concen-
trations and response against speci¢c antigens is found
to be preserved, even in individuals with severe PiZZ
homozygote de¢ciency (4).
Asthma is currently interpreted as an in£ammatory
disease in which di¡erent lymphocytic subpopulations
play a decisive role (12).The defect in a regulating protein
such as AAT might favour hyperactivity of these cells,
which would trigger an in£ammatory cascade, the ¢nal
manifestation of which would be the development, or
reinforcement, of the bronchial asthma. However, the
results of the present work, along with others, do not
support an aetiologic role of the AAT de¢ciency in adult
asthma, at least regarding the partial de¢ciency
presented by heterozygote individuals. The presence of
192 RESPIRATORYMEDICINEa de¢cient allele and exposure to determinant irritants
or environmental allergens may be required for the
risk of the onset of asthma in adults to be increased
(31). On the other hand, other works suggest that
heterozygote phenotypes may, in themselves, increase
the risk of bronchial hyper-responsiveness, and deter-
minegreater severityof the asthmatic disease in children
(6,8,9,19^21).
The importance of the severe homozygote de¢ciency
in the aetiology of asthma has not been established and
will be di⁄cult to evaluate owing to the scant number of
PiZZ homozygote patients and their high risk of
emphysema, which hinders the study of the clinical
symptoms of asthma.
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